[CNBC Television] The Dow Chemical Company CEO: International Projects | Mad Money | CNBC
🎯 Загружено автоматически через бота:
🚫 Оригинал видео:
📺 Данное видео принадлежит каналу «CNBC Television» (@CNBCtelevision). Оно представлено в нашем сообществе исключительно в информационных, научных, образовательных или культурных целях. Наше сообщество не утверждает никаких прав на данное видео. Пожалуйста, поддержите автора, посетив его оригинальный канал.
✉️ Если у вас есть претензии к авторским правам на данное видео, пожалуйста, свяжитесь с нами по почте support@, и мы немедленно удалим его.
📃 Оригинальное описание:
With trade concerns looming, could investing in DowDupont be a red flag? Jim Cramer sits down with the CEO of its Dow Chemical division after earnings.
» Subscribe to CNBC:
» Watch more Mad Money here:
» Read more about DowDuPont here:
“Mad Money“ takes viewers inside the mind of one of Wall Street’s most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From ’Wall Street’ to ’Main Street’ to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news:
Watch full episodes:
Follow Mad Money on Twitter:
Like Mad Money on Facebook:
Follow Cramer on Twitter:
Connect with CNBC News Online!
Visit :
Find CNBC News on Facebook:
Follow CNBC News on Twitter:
Follow CNBC News on Google :
Follow CNBC News on Instagram:
The Dow Chemical Company CEO: International Projects | Mad Money | CNBC
1 view
52
9
1 month ago 00:03:30 1
[CNBC Television] Two experts discuss what happens to inflation in 2023
1 month ago 00:01:55 1
[CNBC Television] Coronavirus: Here’s an inside look at General Motors’ face mask plant
1 month ago 00:07:10 1
[CNBC Television] GSK CEO: Pfizer venture creates value for both our consumer and pharma businesses